Feasibility of Using a Novel Drop-In Gamma Probe for 99mTc-PSMA-I&S-Guided Lymph Node Detection During Robot-Assisted Radical Prostatectomy for Primary Prostate Cancer.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
medline:
5
7
2024
pubmed:
5
7
2024
entrez:
5
7
2024
Statut:
aheadofprint
Résumé
Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (RGS) has gained increased interest in prostate cancer (PCa). This analysis aims to evaluate the feasibility, safety, and limitations of RGS with a novel drop-in gamma probe in primary PCa. The data of 13 patients with primary PCa undergoing RGS were analyzed retrospectively. After preoperative administration of 99mTc-PSMA-I&S, a SPECT/CT was conducted and a robotic radical prostatectomy was performed the following day including intraoperative assessment of the lymph node stations using a novel robotic drop-in gamma probe. This was followed by an extended pelvic lymph node dissection (ePLND) with ex vivo control measurement using the drop-in and a conventional rigid gamma probe. Eleven patients (median PSA value of 11 ng/mL) had high-risk and 2 patients had intermediate-risk PCa. Overall, a median of 22 ePLND lymph nodes were dissected. In 1 patient, preoperative SPECT/CT imaging showed suspicious lymph nodes, which could be confirmed intraoperatively with the robotic drop-in probe and subsequently in the final histopathological analysis. RGS failed to identify 2 patients with micrometastases (<3 mm) preoperatively and intraoperatively. No postoperative complications related to 99mTc-PSMA-I&S RGS or ePLND occurred. RGS with the novel drop-in gamma probe and 99mTc-PSMA-I&S allows for a reliable intraoperative screening for lymph node metastases in robot-assisted radical prostatectomy for primary PCa with an acceptable safety profile. However, limitations in the detection of micrometastases need to be overcome before omitting extended ePLND in patients at risk for lymphatic spread.
Identifiants
pubmed: 38968541
doi: 10.1097/RLU.0000000000005385
pii: 00003072-990000000-01210
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: No external funding or sponsorship was received for this study or publication of this article. N.N.H. has received honoraria for presentations from Intuitive Surgical, Janssen, and Pajunk, and compensation for travel from Bayer, Astellas, Pfizer, and Janssen. C.F. has obtained compensation for travel by Lightpoint. O.K. has received compensation for travel from Astellas.
Références
Anon: EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.
Oderda M, Diamand R, Albisinni S, et al. Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. BJU Int. 2021;127:318–325.
Di Pierro GB, Salciccia S, Frisenda M, et al. Comparison of four validated nomograms (Memorial Sloan Kettering Cancer Center, Briganti 2012, 2017, and 2019) predicting lymph node invasion in patients with high-risk prostate cancer candidates for radical prostatectomy and extended pelvic lymph node dissection: clinical experience and review of the literature. Cancer. 2023;15:1683.
Wawroschek F, Vogt H, Weckermann D, et al. The sentinel lymph node concept in prostate cancer—first results of gamma probe-guided sentinel lymph node identification. Eur Urol. 1999;36:595–600.
Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–466.
Małkiewicz B, Bugla B, Czarnecki M, et al. Diagnostic value of radio-guided sentinel node detection in patients with prostate cancer undergoing radical prostatectomy with modified-extended lymphadenectomy. Cancer. 2022;14:5012.
Wit EMK, Acar C, Grivas N, et al. Sentinel node procedure in prostate cancer: a systematic review to assess diagnostic accuracy. Eur Urol. 2017;71:596–605.
Cacciamani GE, Maas M, Nassiri N, et al. Impact of pelvic lymph node dissection and its extent on perioperative morbidity in patients undergoing radical prostatectomy for prostate cancer: a comprehensive systematic review and meta-analysis. Eur Urol Oncol. 2021;4:134–149.
Gandaglia G, Mazzone E, Stabile A, et al. Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: results of a planned interim analysis of a prospective phase 2 study. Eur Urol. 2022;82:411–418.
Gondoputro W, Scheltema MJ, Blazevski A, et al. Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer. J Nucl Med. 2022;63:1659–1664. jnumed.121.263743.
Lunger L, Steinhelfer L, Korn P, et al. Prostate-specific membrane antigen–radioguided surgery facilitates pelvic lymph node dissection during radical prostatectomy for the treatment of locally advanced prostate cancer with regional lymph node metastases. Eur Urol Oncol. 2023;6:95–98.
Yılmaz B, Şahin S, Ergül N, et al. 99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients. Ann Nucl Med. 2022;36:597–609.
Leeuwen FWB van, Oosterom MN van, Meershoek P, et al.: Minimal-invasive robot-assisted image-guided resection of prostate-specific membrane antigen–positive lymph nodes in recurrent prostate cancer. Clin Nucl Med 2019; 44: 580–581.
Gandaglia G, Ploussard G, Valerio M, et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies. Eur Urol. 2019;75:506–514.
Robu S, Schottelius M, Eiber M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58:235–242.
Abascal Junquera JM, Mestre-Fusco A, Grootendorst MR, et al. Sentinel lymph node biopsy in prostate cancer using the SENSEI® drop-in gamma probe. Clin Nucl Med. 2022;47:86–87.
Abascal Junquera JM, Harke NN, Walz JC, et al. A drop-in gamma probe for minimally invasive sentinel lymph node dissection in prostate cancer: preclinical evaluation and interim results from a multicenter clinical trial. Clin Nucl Med. 2023;48:213–220.
Hinsenveld FJ, Wit EMK, van Leeuwen PJ, et al. Prostate-specific membrane antigen PET/CT combined with sentinel node biopsy for primary lymph node staging in prostate cancer. J Nucl Med. 2020;61:540–545.
Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635–1642.
Maurer T, Robu S, Schottelius M, et al. 99mTechnetium-based prostate-specific membrane antigen–radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;75:659–666.
Dell’Oglio P, Meershoek P, Maurer T, et al. A DROP-IN gamma probe for robot-assisted radioguided surgery of lymph nodes during radical prostatectomy. Eur Urol. 2021;79:124–132.
Berliner C, Steinhelfer L, Chantadisai M, et al. Delayed imaging improves lesion detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in recurrent prostate cancer. J Nucl Med. 2023;64:1036–1042.
de Barros HA, van Oosterom MN, Donswijk ML, et al. Robot-assisted prostate-specific membrane antigen-radioguided salvage surgery in recurrent prostate cancer using a drop-in gamma probe: the first prospective feasibility study. Eur Urol. 2022;82:97–105.
Mix M, Schultze-Seemann W, von Büren M, et al. 99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle. EJNMMI Res. 2021;11:22.
Conti A, Santoni M, Burattini L, et al. Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World J Urol. 2017;35:517–526.
Maxeiner A, Grevendieck A, Pross T, et al. Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer. Aktuelle Urol. 2019;50:612–618.
Derlin T, Riethdorf S, Schumacher U, et al. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate. 2023;83:1076–1088.
Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469–478.
Barros HA de, Oosterom MN van, Leeuwen FWB van, et al.: Real-time identification of nodal metastases with 99mTc–prostate-specific membrane antigen–based radioguidance and indocyanine green fluorescence imaging in primary prostate cancer surgery—on the road to hybrid image-guided surgery. Clin Nucl Med 2023; 48: 697–698.
Lestingi JFP, Guglielmetti GB, Trinh Q-D, et al. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial. Eur Urol. 2021;79:595–604.
Touijer KA, Sjoberg DD, Benfante N, et al. Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial. Eur Urol Oncol. 2021;4:532–539.
McCulloch P, Altman DG, Campbell WB, et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374:1105–1112.